Drug intelligence / Profile preview

TRN-004

Development stage: Preclinical
Lead developer: Turn Biotechnologies
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
Administration: Ophthalmic

Overview

TRN-004 is an investigational ophthalmic therapeutic being developed by Turn Biotechnologies for the rejuvenation of ocular tissues. It is a tailored protein cocktail produced using the proprietary mRNA-based ERA™ (Epigenetic Reprogramming of Aging) platform. The drug is designed to target multiple cell types in the eye, including corneal, limbal, and conjunctival epithelial cells, as well as corneal endothelial cells. By delivering mRNA that encodes specific reprogramming factors, TRN-004 aims to reduce inflammation, oxidative stress, and cellular senescence. It is currently being developed to treat age-related vision conditions and various eye diseases for which no curative treatments are available.

Other names: TRN-004TRN004TRN 004

Beyond the preview

Go deeper on TRN-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRN-004.